

VERTEX PHARMACEUTICALS INC.

ISIN: **US92532F1003** WKN: **92532F100**

Overview

2023/06/08 17:32:27

Price

306.10 EUR

Difference  0.08% (0.25)

General attributes

ISIN US92532F1003

Symbol VRTX

Exchange Vienna Stock Exchange

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 79,459 EUR

Benchmark S&P 500

Market data

Bid (Bid size) -

Ask (Ask size) -

Open 302.90 EUR

High 306.10 EUR

Low 302.90 EUR

Close (prev. day) 305.85 EUR

VWAP 307.80 EUR

Volume (pcs) 0

Trading volume 0.00

Number of trades 2

Last size 0

Futures and Options

Related Futures -

Related Options -

PDF Downloads

Company report: VERTEX PHARMACEUTICALS INC. 

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

| on instrument | on sector | on market | |
|---------------|---|-----------------------|---|
| Date | | Headline | Download |
| 2023/06/06 |  | Global Equity Ratings |  |
| 2023/06/01 |  | Global Equity Ratings |  |
| 2023/05/24 |  | Global Equity Ratings |  |
| 2023/05/03 |  | Global Equity Ratings |  |
| 2023/04/25 |  | Global Equity Ratings |  |

Details

2023/06/08 17:32:27

Price

306.10 EUR

Difference ▲ 0.08% (0.25)

General attributes

ISIN US92532F1003

Symbol VRTX

Exchange Vienna Stock Exchange

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 79,459 EUR

Benchmark S&P 500

Market data

Bid (Bid size) -

Ask (Ask size) -

Open 302.90 EUR

High 306.10 EUR

Low 302.90 EUR

Close (prev. day) 305.85 EUR

VWAP 307.80 EUR

Volume (pcs) 0

Trading volume 0.00

Number of trades 2

Last size 0

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|--------|---------|---------|
| Perf (%) | -0.16% | +19.59% | +31.15% |
| Perf (abs.) | -0.50 | +50.15 | +72.70 |
| Beta | 0.53 | 0.61 | 0.64 |
| Volatility | 22.23 | 28.49 | 31.27 |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.) 307.96 EUR (49)

Ø price 30 days | Ø volume 30 days (pcs.) 311.55 EUR (37)

Ø price 100 days | Ø volume 100 days (pcs.) 292.56 EUR (21)

Ø price 250 days | Ø volume 250 days (pcs.) 290.24 EUR (27)

YTD High | date 320.90 EUR (2023/05/15)

YTD Low | date 262.95 EUR (2023/01/10)

52 Weeks High | date 321.40 EUR (2022/11/04)

52 Weeks Low | date 235.05 EUR (2022/06/16)

All listings for VERTEX PHARMACEUTICALS INC.

| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
|-----------------------|------------|-------|------------|-----------------------|------------------|
| Xetra | 2023/06/08 | 17:35 | 306.10 EUR | 0.00 | 2 |
| Vienna Stock Exchange | 2023/06/08 | 17:32 | 306.10 EUR | 0.00 | 2 |
| Tradegate | 2023/06/08 | 22:26 | 308.55 EUR | 0.12 | 9 |
| Stuttgart | 2023/06/08 | 20:43 | 307.60 EUR | 0.00 | 4 |
| Nasdaq | 2023/06/08 | 22:00 | 332.58 USD | 478.79 | 32,280 |

| | | | | | | |
|-----------------------|------------|-------|--------|-----|------|----|
| | 08 | | | | | |
| Munich | 2023/06/08 | 08:00 | 300.90 | EUR | 0.00 | 2 |
| London Stock Exchange | 2023/06/05 | 15:30 | 334.00 | USD | 0.00 | 1 |
| Hanover | 2023/06/08 | 08:11 | 301.95 | EUR | 0.00 | 1 |
| Hamburg | 2023/06/08 | 08:11 | 301.95 | EUR | 0.00 | 1 |
| Frankfurt | 2023/06/08 | 08:02 | 302.00 | EUR | 0.00 | 1 |
| Duesseldorf | 2023/06/08 | 21:00 | 307.95 | EUR | 0.00 | 12 |
| Berlin | 2023/06/08 | 08:08 | 301.95 | EUR | 0.00 | 1 |
| BX Swiss | 2023/05/19 | 18:00 | 310.97 | CHF | 0.01 | 1 |

Company profile

Company Logo



Contact Details

VERTEX PHARMACEUTICALS INC.

--

50 Northern Avenue - 02210 Boston

Telefon: +1-617-341-6100

Fax: +

E-mail: mediainfo@vrtx.com

PDF Downloads

Company report: VERTEX
PHARMACEUTICALS INC.



Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Members of Management Board

| | |
|--------------------------|--------------------------------|
| Jeffrey Leiden | Chairman of Board of Directors |
| Alan Garber | Member of Board of Directors |
| Sangeeta Bhatia | Member of Board of Directors |
| Bruce Sachs | Member of Board of Directors |
| Diana McKenzie | Member of Board of Directors |
| Lloyd Carney | Member of Board of Directors |
| Suketu Upadhyay | Member of Board of Directors |
| Terrence Kearney | Member of Board of Directors |
| Reshma Kewalramani, M.D. | Chairman of Managing Board |
| David Altshuler | Member of Executive Committee |
| Jeffrey Leiden | Member of Executive Committee |
| Amit K. Sachdev | Member of Executive Committee |
| Bastiano Sanna, Ph.D. | Member of Executive Committee |
| Carmen Bozic, M.D. | Member of Executive Committee |
| Charles F. Wagner, Jr. | Member of Executive Committee |
| Damian Wimot | Member of Executive Committee |
| Joy Liu | Member of Executive Committee |
| Ludovic Fenaux | Member of Executive Committee |
| Mark Bunnage | Member of Executive Committee |
| Michael Partridge | Member of Executive Committee |
| Mike Tirozzi | Member of Executive |

| | |
|--------------------|-------------------------------|
| | Committee |
| Nia Tatsis, Ph.D. | Member of Executive Committee |
| Nina Devlin | Member of Executive Committee |
| Paul Negulescu | Member of Executive Committee |
| Stephanie Franklin | Member of Executive Committee |